Wavepaths

Wavepaths is a London-based neurotechnology company developing AI-driven music tools purpose-built for psychedelic-assisted therapy. The company's core platform dynamically generates and personalizes sound environments in real time, adapting to patient emotional states throughout the arc of a therapeutic session. Rather than relying on static playlists, Wavepaths uses generative music technology informed by neuroscientific principles to create responsive auditory experiences that support deeper therapeutic outcomes. Their tools are designed for use by trained therapists and clinicians, positioning the technology as a clinical support instrument rather than a consumer product.

Wavepaths has raised $3 million in seed funding, reflecting early investor confidence in the intersection of AI, music, and psychedelic medicine. The company has built relationships within the emerging psychedelic-assisted therapy ecosystem, working alongside researchers and clinicians exploring treatments for conditions such as depression, PTSD, and anxiety. Their work aligns with a broader wave of clinical progress in psychedelic medicine, as organizations like MAPS and institutions such as Johns Hopkins have validated the therapeutic potential of compounds like MDMA and psilocybin. Wavepaths is positioning itself as foundational infrastructure within these treatment protocols as the field moves toward regulatory approval and broader clinical adoption.

Wavepaths represents a meaningful convergence of neuroscience, artificial intelligence, and therapeutic design at a critical moment for mental health innovation. By recognizing that the therapeutic environment, and specifically music, plays a measurable role in psychedelic treatment outcomes, the company is addressing a largely overlooked variable in clinical protocol design. Their approach introduces a new category of neurotech tooling that sits at the interface of sensory neuroscience and mental health care delivery. As psychedelic-assisted therapies move closer to mainstream clinical use, Wavepaths stands to become an important enabler of standardized, scalable, and personalized treatment experiences across the industry.